Netherton’s syndrome is a rare inherited skin disorder that affects the skin’s protective barrier, hair growth, and immune system function. The journey through treatment involves careful management of symptoms, prevention of complications, and participation in research exploring new therapeutic approaches that may improve quality of life and address the underlying causes of this challenging condition.
Managing a Complex Genetic Skin Disorder
Treatment of Netherton’s syndrome focuses on several important goals: protecting the fragile skin barrier, preventing dangerous infections, managing immune reactions such as allergies and eczema, and supporting normal growth and development. The approach to treatment must be highly individualized because the severity of symptoms varies considerably from person to person. Some individuals experience severe complications throughout life, while others see improvement as they grow older, though challenges typically persist into adulthood.[1][2]
The disease affects multiple body systems, which means treatment plans must address not only skin problems but also hair abnormalities, immune dysfunction, nutritional challenges, and growth difficulties. Because the skin loses its normal protective function and becomes “leaky,” affected individuals lose essential fluids, proteins, and heat through their damaged skin barrier. This makes them vulnerable to dehydration, infection, and difficulty maintaining body temperature.[6][14]
Medical societies recommend a coordinated approach involving dermatologists, immunologists, nutritionists, and other specialists working together. The first year of life is typically the most critical period, requiring intensive medical supervision and often repeated hospitalizations. However, treatment needs continue throughout life, with strategies adjusted as symptoms change and new complications emerge.[3][6]
Standard Treatment Approaches
The cornerstone of standard treatment for Netherton’s syndrome involves intensive skin care with emollients, which are moisturizing products that help keep the skin hydrated and reduce excessive flaking. These must be applied frequently throughout the day to maintain skin moisture and prevent cracking. Healthcare providers often recommend thick, greasy ointments rather than lighter lotions because they provide better barrier protection and prevent water loss through the damaged skin.[2][9]
Keratolytic agents are medications that help soften and remove thick, scaly skin. These include creams containing urea, lactic acid, or salicylic acid. By reducing the buildup of dead skin cells, these treatments can improve skin appearance and comfort. However, they must be used carefully because the abnormally thin skin in Netherton’s syndrome absorbs substances much more readily than normal skin, which can lead to excessive absorption and potential side effects.[2][9]
Antibiotics play a crucial role in treatment because skin infections are common and can become life-threatening. When infections develop, oral or intravenous antibiotics may be needed. Some individuals require repeated courses of antibiotics throughout their lives. Preventing infection through good skin care, avoiding skin injury, and recognizing early signs of infection are essential strategies that families must learn.[2][6]
Managing immune-related problems is another important aspect of standard care. Many people with Netherton’s syndrome develop food allergies (especially to nuts and fish), hay fever, asthma, and atopic eczema, which is an inflammatory skin condition causing itching and redness. These allergic manifestations require appropriate treatment with antihistamines for allergies, inhalers for asthma, and careful avoidance of known allergens.[2][9]
The use of topical steroids (corticosteroid creams or ointments) presents special challenges in Netherton’s syndrome. While these anti-inflammatory medications can be helpful for older children with eczema, they are absorbed excessively through the damaged skin barrier, especially in infants with widespread skin inflammation. This excessive absorption can cause serious complications including pituitary adrenal axis suppression, which means the body’s natural stress hormone system stops working properly. For this reason, topical steroids must be used with great caution and under close medical supervision.[2][9]
Oral retinoids such as acitretin and isotretinoin have been tried in some patients. These medications are related to vitamin A and can affect skin cell growth and shedding. However, results have been disappointing in Netherton’s syndrome, and these treatments may actually make the skin worse rather than better. For this reason, they are not routinely recommended.[2][9]
Nutritional support is often necessary, especially in children who fail to thrive. Extra protein in the diet helps replace what is lost through the leaky skin. Some infants require feeding tubes or special formulas to ensure adequate nutrition and weight gain. Growth hormone therapy has been used in some children to help maximize height potential, as short stature is common in this condition.[4][12]
Regular ear care is important because dead skin cells accumulate in the ear canals and can affect hearing if not removed. Ophthalmology care may be needed for eye problems such as excessive watering. A comprehensive daily routine typically includes two showers or baths per day followed by generous application of moisturizers and any prescribed medications.[1][12]
Emerging Treatments in Clinical Trials
Research into new treatments for Netherton’s syndrome has accelerated in recent years as scientists have gained deeper understanding of the underlying molecular problems. The condition is caused by mutations in the SPINK5 gene, which provides instructions for making a protein called LEKT1. This protein normally controls enzymes called serine peptidases that break down proteins in the outer layer of skin. When LEKT1 doesn’t work properly, these enzymes become overactive and break down too many proteins, resulting in excessive skin shedding and a defective skin barrier.[1][4]
Recent research has also revealed that the lack of LEKT1 function leads to elevated levels of inflammatory molecules in the IL-17 and IL-36 pathways. These cytokines are signaling proteins that promote inflammation, and their excessive activity contributes to the red, inflamed appearance of the skin and may worsen the barrier defect.[10][15]
Intravenous immunoglobulin therapy, sometimes abbreviated as IVIG, has emerged as an important treatment option based on clinical experience. Immunoglobulin is a mixture of antibodies collected from healthy blood donors. Regular infusions of immunoglobulin have been shown to help some patients with Netherton’s syndrome, particularly those with immune dysfunction. Research has demonstrated that individuals with this condition may have abnormal levels of immunoglobulins (typically high IgE and low to normal IgG) and immature natural killer cells with reduced function. IVIG therapy can improve the function of these immune cells, although exactly how this works is not fully understood. This treatment has become established in some centers as a preferred approach for managing the immune aspects of the disease.[4][7]
Several biological therapies targeting specific inflammatory pathways are being investigated in clinical studies. These are sophisticated medications designed to block specific molecules involved in inflammation. Because Netherton’s syndrome involves overactivity of the IL-17 and IL-36 inflammatory pathways, drugs that block these pathways are logical candidates for testing. Some of these biological therapies are already approved for other skin conditions such as psoriasis, and researchers are evaluating whether they might be effective for Netherton’s syndrome.[7][8]
Clinical trials are examining various biological agents in both children and adults with Netherton’s syndrome. These studies typically progress through different phases. Phase I trials focus primarily on safety, determining whether a treatment is safe enough to give to patients and what dose should be used. Phase II trials examine whether the treatment actually works and continues to monitor safety in more patients. Phase III trials compare the new treatment with standard care or placebo in large numbers of patients to definitively prove effectiveness.[7][8]
A systematic review examining outcomes of various systemic treatments (meaning treatments taken internally rather than applied to the skin) found that different approaches have been tried in both children and adults. These included various immunosuppressive medications, biological therapies, and other systemic agents. The review highlighted the need for more organized research with consistent measures of improvement so that different treatments can be properly compared.[8]
Research centers in Paris, Rotterdam, and other locations have been particularly active in studying Netherton’s syndrome and developing new treatment approaches. International collaboration through networks of experts and patient registries is helping to advance understanding of this rare condition and accelerate the development of new therapies.[8][16]
Gene therapy represents a potential future direction for treatment. Since Netherton’s syndrome is caused by mutations in a single gene (SPINK5), theoretically it might be possible to correct the genetic defect or deliver a working copy of the gene to skin cells. However, this approach is still in early research stages and significant technical challenges must be overcome before gene therapy could become a reality for patients with this condition.[10]
Another research direction involves developing treatments that directly inhibit the overactive serine peptidase enzymes that cause excessive protein breakdown in the skin. Since the fundamental problem in Netherton’s syndrome is that LEKT1 protein cannot properly control these enzymes, medications that block the enzymes’ activity could potentially address the root cause of the skin barrier defect. Scientists are working to identify safe and effective enzyme inhibitors that could be applied to the skin or taken systemically.[1][4]
Clinical research has also focused on better understanding the natural course of the disease and identifying which outcomes are most important to measure in treatment studies. A project called Care4Netherton has worked to define outcome measures that can be used to evaluate whether new treatments are truly helping patients. This work is essential for conducting rigorous clinical trials that can definitively demonstrate whether experimental therapies are beneficial.[16]
Most common treatment methods
- Skin barrier protection and hydration
- Frequent application of emollients (moisturizing ointments and creams) to prevent water loss and maintain skin hydration[2][9]
- Use of keratolytic agents containing urea, lactic acid, or salicylic acid to soften and remove scales[2][9]
- Multiple daily baths or showers followed by immediate moisturizer application[12]
- Infection prevention and treatment
- Anti-inflammatory treatments
- Immunotherapy
- Nutritional support
- Biological therapies (experimental)
- Supportive care
